105
Participants
Start Date
October 20, 2017
Primary Completion Date
July 2, 2020
Study Completion Date
March 31, 2021
Cardiac Drug
"Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group."
Placebos
"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
The John Paul II Hospital, Krakow
Central Clinical Hospital of the MSWiA in Warsaw, Warsaw
Collaborators (1)
KCRI
OTHER
National Center for Research and Development, Poland
OTHER
John Paul II Hospital, Krakow
OTHER